Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Arcus Biosciences Charts.

Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Arcus Biosciences Charts.

Arcus Biosciences Inc News

Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Thursday 27 February 2025 (5 days ago) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Wednesday 26 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Wednesday 26 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 26 February 2025 (6 days ago) • Edgar (US Regulatory)

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
Wednesday 26 February 2025 (6 days ago) • Business Wire

Arcus Biosciences Announces New Employment Inducement Grants
Tuesday 25 February 2025 (7 days ago) • Business Wire

Form 8-K - Current report
Thursday 20 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Wednesday 19 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
Tuesday 18 February 2025 (2 weeks ago) • Business Wire

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
Tuesday 18 February 2025 (2 weeks ago) • Business Wire

Form 8-K - Current report
Tuesday 18 February 2025 (2 weeks ago) • Edgar (US Regulatory)

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
Sunday 16 February 2025 (2 weeks ago) • Business Wire

More Arcus Biosciences Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions